Vladimir Chulanov

6.7k total citations
115 papers, 1.5k citations indexed

About

Vladimir Chulanov is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Vladimir Chulanov has authored 115 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Epidemiology, 57 papers in Hepatology and 37 papers in Molecular Biology. Recurrent topics in Vladimir Chulanov's work include Hepatitis B Virus Studies (56 papers), Hepatitis C virus research (55 papers) and Liver Disease Diagnosis and Treatment (35 papers). Vladimir Chulanov is often cited by papers focused on Hepatitis B Virus Studies (56 papers), Hepatitis C virus research (55 papers) and Liver Disease Diagnosis and Treatment (35 papers). Vladimir Chulanov collaborates with scholars based in Russia, United States and Germany. Vladimir Chulanov's co-authors include Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Dieter Glebe, E. V Volchkova, Irina Goptar, Andrey A. Zamyatnin, Brian J. McMahon, James Williams and Stephen Livingston and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Vladimir Chulanov

93 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vladimir Chulanov Russia 18 744 636 594 185 102 115 1.5k
Chunchen Wu China 24 688 0.9× 406 0.6× 596 1.0× 244 1.3× 185 1.8× 68 1.4k
Yongshui Fu China 23 837 1.1× 334 0.5× 784 1.3× 240 1.3× 331 3.2× 120 1.8k
Cathy Royer France 20 600 0.8× 284 0.4× 628 1.1× 264 1.4× 228 2.2× 41 1.5k
Justin B. Robbins United States 16 411 0.6× 411 0.6× 607 1.0× 55 0.3× 75 0.7× 17 1.3k
Dmitry Kostyushev Russia 16 203 0.3× 632 1.0× 101 0.2× 82 0.4× 66 0.6× 64 943
Ramin Sarrami‐Forooshani Iran 16 291 0.4× 335 0.5× 191 0.3× 215 1.2× 274 2.7× 45 991
María J. Gómara Spain 22 249 0.3× 554 0.9× 166 0.3× 217 1.2× 192 1.9× 81 1.3k
Hui‐Lin Wu Taiwan 18 626 0.8× 307 0.5× 439 0.7× 218 1.2× 191 1.9× 34 1.1k
Rouhollah Vahabpour Iran 19 226 0.3× 293 0.5× 105 0.2× 130 0.7× 85 0.8× 65 759
Guocai Zhong China 17 1.7k 2.3× 721 1.1× 1.2k 2.1× 702 3.8× 432 4.2× 30 2.8k

Countries citing papers authored by Vladimir Chulanov

Since Specialization
Citations

This map shows the geographic impact of Vladimir Chulanov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Chulanov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Chulanov more than expected).

Fields of papers citing papers by Vladimir Chulanov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Chulanov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Chulanov. The network helps show where Vladimir Chulanov may publish in the future.

Co-authorship network of co-authors of Vladimir Chulanov

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Chulanov. A scholar is included among the top collaborators of Vladimir Chulanov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Chulanov. Vladimir Chulanov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brezgin, Sergey, Anastasiya Kostyusheva, Vladimir Chulanov, et al.. (2025). Overcoming Antibiotic Resistance and Treating Bacterial Infections with Biological Nanoparticles. International Journal of Molecular Sciences. 26(24). 11780–11780.
2.
Brezgin, Sergey, Anastasiya Kostyusheva, Н.В. Пономарева, et al.. (2024). Basic Guide for Approaching Drug Delivery with Extracellular Vesicles. International Journal of Molecular Sciences. 25(19). 10401–10401. 12 indexed citations
3.
Kostyusheva, Anastasiya, Sergey Brezgin, Н.В. Пономарева, et al.. (2024). Clinical and Translational Landscape of Viral Gene Therapies. Cells. 13(22). 1916–1916. 5 indexed citations
4.
Pimenov, Nikolay, et al.. (2024). Features of the covid-19 epidemic and characteristics of patients during the spread of the delta SARS-COV-2 in Russia. SHILAP Revista de lepidopterología. 16(3). 45–55.
5.
Авдеев, С. Н., Vladimir Chulanov, Е.I. Alexeeva, et al.. (2023). The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic. Terapevticheskii arkhiv. 95(8). 722–729. 1 indexed citations
6.
Brezgin, Sergey, Anastasiya Kostyusheva, Ekaterina Bayurova, et al.. (2023). Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics. Pharmaceutics. 15(2). 534–534. 9 indexed citations
7.
Buti, Marı́a, Heiner Wedemeyer, Soo Aleman, et al.. (2023). Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks. Zeitschrift für Gastroenterologie. 61(1). e47–e47.
8.
Chulanov, Vladimir, K. K. Kyuregyan, Yu. V. Ostankova, et al.. (2022). Genetic Diversity and Possible Origins of the Hepatitis B Virus in Siberian Natives. Viruses. 14(11). 2465–2465. 2 indexed citations
9.
Maurer, Florian P., Natalia Shubladze, Giorgi Kuchukhidze, et al.. (2022). Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region. Journal of Molecular Diagnostics. 24(11). 1189–1194. 5 indexed citations
10.
Kostyushev, Dmitry, et al.. (2021). CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Therapeutics. 32(1). 14–28. 4 indexed citations
11.
Popping, Stephanie, Valeria Cento, Carole Seguin‐Devaux, et al.. (2021). The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. Viruses. 14(1). 16–16. 4 indexed citations
12.
Bogomolov, Pavel, В. Т. Ивашкин, И. В. Маев, et al.. (2021). Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis. Terapevticheskii arkhiv. 93(11). 1290–1299. 1 indexed citations
13.
Kostyushev, Dmitry, et al.. (2021). May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?. Advances in Therapy. 39(1). 430–440. 7 indexed citations
14.
Pshenichnaya, N., et al.. (2021). Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. Terapevticheskii arkhiv. 93(11). 1306–1315. 1 indexed citations
15.
Chulanov, Vladimir, Д. А. Гусев, Isakov Va, et al.. (2020). Narlaprevir, ritonavir, and sofosbuvir in non-cirrhotic chronic hepatitis C genotype 1 infected patients. 9(1). 50–56.
16.
Tkachuk, Artem P., Vladimir Chulanov, С. Б. Фитилев, et al.. (2020). Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines. 8(4). 652–652. 49 indexed citations
17.
18.
Chulanov, Vladimir, et al.. (2016). Лечение гепатита С у реципиентов печени в Московском центре трансплантации печени в течение 10 лет. 5–12.
19.
Rakhmanova, Aza, et al.. (2013). Оценка социально-экономического бремени гепатита с в Российской Федерации. 1 indexed citations
20.
Livingston, Stephen, Josephine Simonetti, Brian J. McMahon, et al.. (2006). Hepatitis B Virus Genotypes in Alaska Native People with Hepatocellular Carcinoma: Preponderance of Genotype F. The Journal of Infectious Diseases. 195(1). 5–11. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunchen Wu Breakdown of academic impact, for papers by Yongshui Fu Breakdown of academic impact, for papers by Cathy Royer Breakdown of academic impact, for papers by Justin B. Robbins Breakdown of academic impact, for papers by Dmitry Kostyushev Breakdown of academic impact, for papers by Ramin Sarrami‐Forooshani Breakdown of academic impact, for papers by María J. Gómara Breakdown of academic impact, for papers by Hui‐Lin Wu Breakdown of academic impact, for papers by Rouhollah Vahabpour Breakdown of academic impact, for papers by Guocai Zhong
Rankless by CCL
2026